	US 12,319,943 B2
	Mutant protease
Masatoshi Tohata, Utsunomiya (JP)
Assigned to Kao Corporation, Tokyo (JP)
Appl. No. 17/435,853
Filed by Kao Corporation, Tokyo (JP)
PCT Filed Mar. 6, 2020, PCT No. PCT/JP2020/009570 § 371(c)(1), (2) Date Sep. 2, 2021, PCT Pub. No. WO2020/184410, PCT Pub. Date Sep. 17, 2020.
Claims priority of application No. 2019-044267 (JP), filed on Mar. 11, 2019.
Prior Publication US 2022/0154109 A1, May 19, 2022
Int. Cl. C12N 9/56 (2006.01); C11D 3/386 (2006.01); C12N 9/54 (2006.01); C12N 15/75 (2006.01); C12P 21/02 (2006.01)

CPC C12N 9/54 (2013.01) [C11D 3/38618 (2013.01); C12N 15/75 (2013.01); C12P 21/02 (2013.01)]

22 Claims

1. A mutant protease that consists of an amino acid sequence having an identity of at least 90% with the amino acid sequence as shown in SEQ ID NO: 2 and that has an amino acid residue selected from the group of consisting of aspartic acid, glutamic acid, phenylalanine, histidine, isoleucine, methionine, proline, glutamine, threonine, valine, tryptophan, and tyrosine at a position corresponding to position 303 of the amino acid sequence as shown in SEQ ID NO:2.